Psoriatic Arthritis News

Treat-to-target tapering of TNF inhibitors in patients with psoriatic arthritis or axial spondyloarthritis does not result in any negative impact on disease activity, compared with the full dose, according to data published in Rheumatology.

Patients with psoriasis who use biologics are more likely to develop psoriatic arthritis than those on other or no therapies, according to retrospective data published in the Annals of the Rheumatic Diseases.

Diagnoses of arthritis, axial symptoms and tendonitis or enthesitis often increase over time before a patient is finally diagnosed with psoriatic arthritis, according to data published in Arthritis Research & Therapy.

In this issue’s cover story, experts discussed how reducing psoriasis in the patient is the best way to curb the negative impact on mental health that stems from disease stigma.

Compared to the Rotterdam Early Arthritis Cohort referral rule, the Clinical Arthritis Rule had superior specificity and overall diagnostic performance in recognizing inflammatory arthritis and inflammatory rheumatic disease in primary care.

The FDA has designated Cyltezo the first approved interchangeable biosimilar to treat certain inflammatory diseases, allowing pharmacists to substitute it for Humira without the need for the prescriber to alter the prescription.

Healio announced the launch of Rheum and Boards, a quiz-based, online learning resource for rheumatologists, according to a Healio press release.

Patients with psoriatic arthritis prefer oral over subcutaneous biologics, and prioritize complication avoidance and the ability to work and perform ordinary activities over clinical efficacy, according to data.

Ustekinumab, a biologic targeting cytokines interleukin 12 and 23, has been submitted for expanded approval in the treatment of juvenile psoriatic arthritis in pediatric patients aged 5 years and older, according to a press release.

The live attenuated varicella-zoster vaccine is safe and provides “reasonable short-term” effectiveness in patients receiving TNF inhibitors for a variety of indications, according to data published in the Annals of Internal Medicine.